{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.92","value":"3.15"},{"groupId":"OG001","spread":"0.32","value":"3.33"},{"groupId":"OG002","spread":"1.35","value":"3.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Tumor mutation burden was defined as the number of somatic mutations per megabase. Average tumor mutation burden was reported with a standard deviation. When only one patient was analyzed, the standard deviation was reported as 0 rather than undefined.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.1 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 1, Dose Level 1"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 1, Dose Level 2"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG002","title":"Stratum 1, Dose Level 3"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG003","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG004","title":"Stratum 2, Dose Level 3"}],"paramType":"MEAN","populationDescription":"No Stratum 2 patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Day 0 of treatment","title":"Tumor Mutation Burden Based on RNA Sequencing of Tumor Tissue","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"mutations per megabase"}